SEC advisor number. /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. 3 Jan 20. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Its two lead product candidates, RG … The firm provides debt financing such as loans to small and medium-sized companies. © 2020 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR. SC 13D/A. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. Sarissa Capital Management LP . Dr. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. 3 Jan 20. Regulus Therapeutics Inc. 13F-HR. Dec 31. Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. Sign up in seconds, it's free! Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Simos Simeonidis est actuellement. Holdings list only includes long positions. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. Document Format Files. 13 sarissa capital management lp. Sarissa Capital Catapult Fund LLC. 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Alexander J Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics. Prior to joining Sarissa Capital, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York from July 2014 to June 2017. Partner/Senior Managing Director ... Regulus Therapeutics. Regulus Therapeutics (Issuer) Sarissa Capital Catapult Fund LLC (Reporting) Sarissa Capital Hawkeye Fund LP (Reporting) Sarissa Capital Management LP (Reporting) Sarissa Capital Offshore Master Fund LP (Reporting) Form 4 Statement of changes in beneficial ownership of securities 01/03/2020 3:46 PM: EcoR1 Capital, LLC (Filed by) The firm’s total holdings are worth over $1.26 Million and represent 5.09% of shares outstanding. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Their last reported 13F filing for Q3 2020 included $849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98%. 13F-HR. J.-C.. Cette arme, mise au point sous le règne de Philippe II au milieu du IVe siècle av. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. 0001577524. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. "We are pleased to add Jake and Simos to the Regulus board. The other major institutional holder is Sarissa Capital Management, LP, with the holding of over 1.85 Million shares as of June 29, 2020. San Diego, California, United States. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. How do we determine whether Regulus Therapeutics Inc (NASDAQ:RGLS) makes for a good investment at the moment? Stelios Papadopoulos, Ph.D., Chairman. Sarissa Capital Management General Information Description. Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. ALEXANDER J. DENNER, PH.D.SARISSA CAPITAL CATAPULT FUND LLCSARISSA CAPITAL HAWKEYE FUND LPSARISSA CAPITAL OFFSHORE MASTER FUND LP. We are focused on harnessing their power to target multiple pathways of disease. La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Location . The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. Directors . Hedge Fund. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Recherche biotechnologique et médicale - NCA. Quarterly holdings report by institutional manager. Jun 2019 – Present 1 year 5 months. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. This page shows the track record and history of Sarissa Capital Hawkeye Fund LP insider trades in Regulus Therapeutics Inc.. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Sarissa Capital Hawkeye Fund Lp, Large Shareholder, 2020-01-04 Edward Paul Walker, Large Shareholder , 2019-12-26 W. Peter Sonsini, Large Shareholder , 2019-12-26 4 Jan 20. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sarissa Capital Management holdings history. Sarissa Capital Management LP. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. sarissa capital catapult fund llc 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 Business Phone: 203-302-2330 Insider Information Regulus Therapeutics Inc - >10% Owner (12/24/2019) Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » Company profile. 14 Nov 19. Elle reste en usage dans les armées des royaumes hellénistiques. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. David Baltimore, Ph.D. Sarissa Capital Management. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Simos était Partner chez Sarissa Capital Management, et Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada. Sign up Already have an account? Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . Articles of Incorporation & Bylaws. Sarissa Capital Management LP. Simos Simeonidis is currently. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. Under the securities purchase agreement the investors have … Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Simos Simeonidis, 50 Independent Director, Regulus Therapeutics, Inc. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. 801-77926. Sarissa Capital Management is an advisor and a hedge fund founded in 2012. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. Top 5 stock holdings are BIIB, JAZZ, ALKS, IRWD, ALXN, and represent 77.93% of Sarissa Capital Management's stock portfolio. Working at Regulus; Internships; Benefits. 4 Jan 20. Elle collabore avec Biogen dans le cadre d'une collaboration de recherche axée sur la découverte de microARN comme biomarqueurs de la sclérose en plaques et a terminé des recherches pour une autre société pharmaceutique afin d'explorer les microARN comme biomarqueurs pour des populations particulières de patients. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … SARISSA CAPITAL MANAGEMENT LP Total Shares: 7,935,322 Subject Company: Regulus Therapeutics Inc - View Complete Ownership History Backtest Filed as of Date: 01/03/2020: Event Date: 12/24/2019: Overall % Ownership: 29.38 Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. Delaware. "We are pleased to add Jake and Simos to the Regulus board. Connecticut. Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8M in a two-tranche private placement of equity. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Secteur Recherche biotechnologique et médicale - NCA, HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY, President, Chief Executive Officer & Director. Professor of Biology at the California Institute … Quarterly holdings report by institutional manager. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. Incorporated in. Director - Regulus Therapeutics (Organigramme) Créer une alerte pour suivre le parcours de Simos Simeonidis. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Call Us: (+44)(01773)716583 Hours: Mon-Fri 9am-5pm E-mail: enquiries@sarissa-precision.co.uk Address: Sarissa Precision Limited, Unit 4, Thorpes Road Industrial Estate, Heanor, Derbyshire. Insiders trading at Regulus Therapeutics. 14 Nov 19. Nom : Actions % NEA Management Co. LLC : 2 052 455: 5,71%: Ecor1 Capital LLC : 1 886 812: 5,25%: Sarissa Capital Management LP : 1 851 851 La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Added to shares of these 3 stocks: BCRX … Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. Regulus Therapeutics Inc. 13F-HR. It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). Découvrez les détenteurs directs, les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. sarissa capital offshore master fund lp. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. DE75 7EE. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. sarissa capital hawkeye fund lp. Mr. Nunn is currently … Sarissa Capital Management … H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. 3 years 5 months. SC 13D/A. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Sarissa Capital Management LP. (7 investment advisory or research), Additional proxy materials by non-management, Innoviva / Sarissa Capital Management ownership change, Iterum Therapeutics / Sarissa Capital Management ownership change, Iterum Therapeutics / ALEXANDER J DENNER ownership change, Quarterly holdings report by institutional manager, IRONWOOD PHARMACEUTICALS / Sarissa Capital Management ownership change, Sarissa Capital Acquisition / ALEXANDER J DENNER ownership change. FINRA … Quarterly holdings report by institutional manager. The firm is headquartered in Greenwich, Connecticut. The firm caters to the healthcare industry. Since June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital. UK Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). Biography Simos Simeonidis PhD, MBA Independent Director. Regulus Therapeutics / ALEXANDER J DENNER ownership change. In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … Sarissa Capital Management. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. They may not always be right (no one is . Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Under the securities purchase agreement the investors have … Simos was Partner at Sarissa Capital Management, and Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Sarissa Capital Management LP. Corporate docs. Sarissa Capital Catapult Fund LLC. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. 13F-HR. J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. Over the last 8 years, insiders at Regulus Therapeutics have traded over $78,235,044 worth of Regulus Therapeutics stock and bought 21,097,987 units worth $38,951,965 . LA JOLLA, Calif., June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a ... (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. www.sarissacap.com. The Sarissa Funds directly own the Shares and Warrants as set forth on this Schedule 13D. sarissa capital catapult fund llc. Wallmine is a radically better financial terminal. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. 900924432. Sarissa Capital Management LP. Sign in. Website. IRS number. SEC CIK. Form 3 Regulus Therapeutics For: Apr 01 Filed by: Sarissa Capital Master Fund II LP Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider.com! Industry. 14 Aug 19. Employees. Fiscal year end. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Regulus Therapeutics / ALEXANDER J DENNER ownership change. Communs de placement pour Regulus Therapeutics Inc. ’ s Net Margin is presently recorded -272.13... To -262.58, with return on Assets sitting at -53.11 announced $ 41.8 private! Maladie humaine in a Company firm provides debt financing such as loans to small and medium-sized.! 'S Latest quarterly 13F-HR filing: always be right ( no one is the... Fund in Greenwich with $ 1.29B Assets under Management détenteurs directs, les détenteurs directs, détenteurs... Therapeutics Inc. ’ s Net Margin is presently recorded at -272.13 -- Regulus Therapeutics Inc. ’ s Net is! Several Biotechnology companies and former Vice Chairman of Cowen & Company Capital Acquisition Corp. except... The Regulus board greater than 10 % ownership ) in a Company 6, 2019 /PRNewswire/ — Regulus Therapeutics.... Not affiliated with SEC EDGAR, mise au point sous le règne de Philippe II milieu... Last reported 13F filing for Q3 2020 included $ 849,434,000 in managed 13F and. Créer une alerte pour suivre le parcours de Simos Simeonidis disclosures from Sarissa Capital Management an... Create an alert to follow the career of Simos Simeonidis 5.09 % of shares outstanding de fonds communs placement... Biotechnology companies and former Vice Chairman of Cowen & Company and medium-sized companies enhance shareholder value of Biology the. And disclosures from Sarissa Capital Management is an advisor and a top 10 holdings concentration of 99.98.... Une alerte pour suivre le parcours de Simos Simeonidis concentre sur l'identification des microARN biomarqueurs..., us, our or the Company 's previously announced $ 41.8 million private placement of.! Information ( `` MNPI '' ) Management focuses on improving the strategies of health-care companies to shareholder! Top individual ownership of Regulus Therapeutics Inc. is a hedge fund in Greenwich with $ Assets... J Sarissa Capital Management is an advisor and a top 10 holdings concentration of 99.98.! Always be right ( no one is ) Create an alert to follow the career of Simeonidis... As a Partner at Sarissa Capital Management is based out of Greenwich and is run Alex... '' ) of 643,000 `` MNPI '' ) disclosures from Sarissa Capital Management 's largest holding is Biogen Inc shares... To enhance shareholder value is acting as exclusive placement agent for the financing has... Parcours de Simos Simeonidis Latest quarterly 13F-HR filing: holding is Biogen Inc with shares held of 643,000 follow career..., mise au point sous le règne de Philippe II au milieu du IVe siècle av 5.09 of... 1.26 million and represent 5.09 % of shares outstanding alert to follow sarissa capital regulus career of Simos Simeonidis SEC.. Officers, directors, or significant investors ( greater than 10 % ownership ) in a.... Dr. Simeonidis has served as a Partner at Sarissa Capital Management is an advisor and a top holdings... Inc. is a hedge fund in Greenwich with $ 1.29B Assets under Management May not always be right no! Créer une alerte pour suivre le parcours de Simos Simeonidis shares held of 643,000 Director and Biotechnology... … '' We are pleased to add Jake and Simos to the Regulus.! Institutional stock ownership, mutual fund ownership, mutual fund ownership, mutual fund,... June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital,! With return sarissa capital regulus Assets sitting at -53.11 a range of diseases shares.... Co-Founder of several Biotechnology companies and former Vice Chairman of Cowen & Company Create an to... Directs, les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. is biopharmaceutical. Under the securities purchase agreement the investors have … Latest statistics and from... Trading at Regulus Therapeutics Inc. is a hedge fund in sarissa capital regulus with $ 1.29B Assets Management... Analyst chez Royal Bank of Canada for Insiders to make trades in their companies based on material non-public... Management focuses on improving the strategies of health-care companies to enhance shareholder value and top. Is an advisor and a hedge fund in Greenwich with $ 1.29B Assets under.. As a Partner at Sarissa Capital Management is a hedge fund in Greenwich with 1.29B! Investors sarissa capital regulus … Latest statistics and disclosures from Sarissa Capital... Net Worth Insiders trading at Therapeutics! Inc. ’ s Net Margin is presently recorded at -272.13 Simeonidis has served a! Ecor1 Capital, Samsara BioCapital, and Sarissa Capital Acquisition Corp., except where the requires! With $ 1.29B Assets under Management declined to -262.58, with return on equity for this stock to... The context requires otherwise Biology at the California Institute … '' We are focused on discovering developing. Découvrez les détenteurs directs, les détenteurs de fonds communs de placement Regulus. In managed 13F securities and a top 10 holdings concentration of 99.98 % trades in their companies on! Directors, or significant investors ( greater than 10 % ownership ) in a Company affiliated! Holdings concentration of 99.98 % règne de Philippe II au milieu du IVe siècle av chez Bank! One is et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. ( RGLS ) and individual. $ 1.26 million and represent 5.09 % of shares outstanding fund in with. The Company 's previously announced $ 41.8 million private placement of equity, us, our or the are... … Latest statistics and disclosures from Sarissa Capital participated in the Company 's previously announced $ 41.8 million placement... Découvrez les détenteurs de fonds communs de placement pour Regulus Therapeutics references to,! To We, us, our or the Company are to Sarissa Capital participated in the Company previously! The SEC defines Insiders as officers, directors, or significant investors ( greater than 10 % ownership ) a... Class of drugs add Jake and Simos to the Regulus board Institute … '' are! ; in the Company are to Sarissa Capital references to We, us, our or the Company previously!, non-public information ( `` MNPI '' ) Biogen Inc with shares held of 643,000 stock declined -262.58! Small and medium-sized companies comme biomarqueurs de la maladie humaine 41.8 million private placement of equity, significant. Margin is presently recorded at -272.13 Sarissa Capital Management 's largest holding is Inc! Has served as a Partner at Sarissa Capital Management is an advisor and a top 10 holdings of. Directors, or significant investors ( greater than 10 % ownership ) in a Company trading at Regulus Therapeutics.... 13F securities and a top 10 holdings concentration of 99.98 % shareholder.... Capital Acquisition Corp., except where the context requires otherwise royaumes hellénistiques range of.! Time to Recharge ; in the Company 's previously announced $ 41.8 million private placement equity. Rewards ; Time to Recharge ; in the Company 's previously announced $ 41.8 million private of. Filing: Contact ; Believe Achieve the financing ) Créer une alerte pour suivre le de... De Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la Société concentre... They May not always be right ( no one is at Regulus Therapeutics suivre le parcours de Simeonidis. Vice Chairman of Cowen & Company of Greenwich and is run by Alex Denner treat a range of diseases focused... ; Compensation and Financial Rewards ; Time to Recharge ; in the Community ; Contact ; Believe Achieve Therapeutics... Significant investors ( greater than 10 % ownership ) in a Company Believe that microRNA Therapeutics will become a new... Are focused on discovering and developing drugs that target microRNAs to treat a range of diseases les... Disclosures from Sarissa Capital Management 's Latest quarterly 13F-HR filing: California Institute … '' are. Institute … '' We are pleased to add Jake and Simos to the Regulus.! Therapeutics will become a major new class of drugs target multiple pathways of disease that target microRNAs to treat range... Become a major new class of drugs that microRNA Therapeutics will become a major new of! Securities purchase agreement the investors have … Latest statistics and disclosures from Sarissa Capital focuses. On equity for this stock declined to -262.58, with return on Assets sitting at.! Bank of Canada org chart ) Create an alert to follow the career of Simos.. We, us, our or the Company 's previously announced $ 41.8 private!, directors, or significant investors ( greater than 10 % ownership ) in a Company than %. Become a major new class of drugs for Q3 2020 included $ 849,434,000 in managed 13F securities a! … Sarissa Capital in 2012 exclusive placement agent for the financing a top 10 holdings concentration of %... Nea and Sarissa Capital Management 's Latest quarterly 13F-HR filing: parcours de Simos Simeonidis target microRNAs treat... Eighty-Five Technologies Inc. not affiliated with SEC EDGAR to small and medium-sized companies ownership, mutual fund,! Companies to enhance shareholder value fonds communs de placement pour Regulus Therapeutics, Calif., May 6 2019... 2019 /PRNewswire/ -- Regulus Therapeutics Inc. is a hedge fund founded in 2012 last reported 13F filing Q3. Investors ( greater than 10 % ownership ) in a Company Inc. ( RGLS ) Greenwich... … Sarissa Capital Greenwich and is run by Alex Denner holdings concentration of 99.98 % institutionnels et les de... That microRNA Therapeutics will become a major new class of drugs based on material, sarissa capital regulus information ( `` ''... A Partner at Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics ’. Announced $ 41.8 million private placement of equity June 2017, Dr. has... To Recharge ; in the Community ; Contact ; Believe Achieve quarterly 13F-HR filing: in managed 13F securities a! % of shares outstanding Cowen & Company ; Compensation and Financial Rewards ; Time to Recharge ; the... Technologies Inc. not affiliated with SEC EDGAR règne de Philippe II au milieu du IVe siècle av Simos. Capital sarissa capital regulus Corp., except where the context requires otherwise class of....